Lite Strategy (LITS) EV to CFO (2010 - 2026)
Lite Strategy (LITS) posted EV to CFO of 21.87 for Q1 2026, down 7.49% on a QoQ basis from 20.34 in Q4 2025, and down 1309.16% year-over-year from 1.81 in Q1 2025.
Analysis
Lite Strategy (LITS) EV to CFO (2010 - 2026) Analysis & Trends
Lite Strategy has reported EV to CFO for 17 years, with the latest figure at 21.87 in Q1 2026.
- On a quarterly basis, EV to CFO fell 1309.16% year-over-year to 21.87 in Q1 2026; TTM through Mar 2026 was 3.19, a 2064.63% decrease from a year earlier, with the FY2025 full-year figure at 0.07, down 80.16% from the prior year.
- EV to CFO was 21.87 for Q1 2026 at Lite Strategy, down from 20.34 in the prior quarter.
- The five-year high for EV to CFO was 28.74 in Q1 2024, with the low at 21.87 in Q1 2026.
- Average EV to CFO over 5 years is 3.64, with a median of 4.65 recorded in 2022.
- The sharpest annual moves came in 2022 and 2026: EV to CFO jumped 2912.52% in 2022, then tumbled 1309.16% in 2026.
- Over 5 years, EV to CFO stood at 14.4 in 2022, then sank by 52.79% to 6.8 in 2023, then sank by 70.52% to 2.0 in 2024, then tumbled by 1114.89% to 20.34 in 2025, then retreated by 7.49% to 21.87 in 2026.
- The last three EV to CFO figures came in at 21.87 (Q1 2026), 20.34 (Q4 2025), and 13.58 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -21.87 |
| Dec 31, 2025 | -20.34 |
| Sep 30, 2025 | -13.58 |
| Jun 30, 2025 | 0.63 |
| Mar 31, 2025 | 1.81 |
| Dec 31, 2024 | 2.00 |
| Sep 30, 2024 | 2.44 |
| Jun 30, 2024 | 1.05 |
| Mar 31, 2024 | 28.74 |
| Dec 31, 2023 | 6.80 |
| Sep 30, 2023 | 6.18 |
| Jun 30, 2023 | 5.03 |
| Mar 31, 2023 | 15.22 |
| Dec 31, 2022 | 14.40 |
| Sep 30, 2022 | 14.21 |
| Jun 30, 2022 | 4.65 |
| Mar 31, 2022 | 14.57 |
| Dec 31, 2021 | 0.48 |
| Sep 30, 2021 | -4.61 |
| Jun 30, 2021 | -2.01 |